labetalol and losartan

labetalol has been researched along with losartan in 14 studies

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (7.14)18.2507
2000's5 (35.71)29.6817
2010's7 (50.00)24.3611
2020's1 (7.14)2.80

Authors

AuthorsStudies
Strassburg, CP; Tukey, RH1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Lombardo, F; Obach, RS; Waters, NJ1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ1
Ekins, S; Williams, AJ; Xu, JJ1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY1
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Abassi, ZA; Cuda, G; Golomb, E; Keiser, HR; Panchal, VR; Stylianou, M; Trachewsky, D1
Weber, MA1
Cervenka, L; Chábová, VČ; Husková, Z; Kompanowska-Jezierska, E; Kopkan, L; Kramer, HJ; Kujal, P; Malý, J; Netuka, I; Opočenský, M; Rakušan, D; Sadowski, J; Schejbalová, S; Skaroupková, P; Vaněčková, I; Vaňourková, Z; Vernerová, Z; Walkowska, A1
Aboul-Enein, HY; Ali, I; ALOthman, ZA; Alsheetan, KM1

Reviews

3 review(s) available for labetalol and losartan

ArticleYear
Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
    Annual review of pharmacology and toxicology, 2000, Volume: 40

    Topics: Autoimmunity; Chromosome Mapping; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Neoplasms; Steroids; Terminology as Topic

2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
The role of the new beta-blockers in treating cardiovascular disease.
    American journal of hypertension, 2005, Volume: 18, Issue:12 Pt 2

    Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Antihypertensive Agents; Atenolol; Benzopyrans; Cardiovascular Diseases; Clinical Trials as Topic; Enalapril; Ethanolamines; Female; Heart Failure; Hemodynamics; Humans; Hypertension; Labetalol; Losartan; Male; Metoprolol; Middle Aged; Nebivolol; Nifedipine; Receptors, Adrenergic, beta-1; Receptors, Adrenergic, beta-2; Sympathomimetics

2005

Other Studies

11 other study(ies) available for labetalol and losartan

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Physicochemical determinants of human renal clearance.
    Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15

    Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight

2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Developing structure-activity relationships for the prediction of hepatotoxicity.
    Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes

2010
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
    Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10

    Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding

2012
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship

2012
Angiotensin II maintains, but does not mediate, isoproterenol-induced cardiac hypertrophy in rats.
    The American journal of physiology, 1994, Volume: 267, Issue:4 Pt 2

    Topics: Actins; Angiotensin II; Animals; Base Sequence; Biphenyl Compounds; Blood Pressure; Captopril; Cardiomegaly; DNA; DNA Primers; Dose-Response Relationship, Drug; Gene Expression; Genes, fos; Heart; Hydralazine; Hydroxyproline; Imidazoles; Isoproterenol; Labetalol; Losartan; Male; Methyldopa; Molecular Sequence Data; Myocardium; Myosins; Polymerase Chain Reaction; Rats; Rats, Sprague-Dawley; RNA; RNA, Messenger; Tetrazoles; Transcription, Genetic

1994
Similar renoprotection after renin-angiotensin-dependent and -independent antihypertensive therapy in 5/6-nephrectomized Ren-2 transgenic rats: are there blood pressure-independent effects?
    Clinical and experimental pharmacology & physiology, 2010, Volume: 37, Issue:12

    Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Creatinine; Diabetic Nephropathies; Diuretics; Drug Therapy, Combination; Furosemide; Hydrochlorothiazide; Hypertension; Indoles; Kidney Failure, Chronic; Labetalol; Losartan; Proteinuria; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Renin; Renin-Angiotensin System

2010
Applications of shun shell column and nanocomposite sorbent for analysis of eleven anti-hypertensive in human plasma.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2020, Jun-01, Volume: 1146

    Topics: Adsorption; Antihypertensive Agents; Chromatography, High Pressure Liquid; Diltiazem; Furosemide; Humans; Hydrochlorothiazide; Irbesartan; Iron; Labetalol; Limit of Detection; Losartan; Metal Nanoparticles; Methyldopa; Nanocomposites; Polyvinyl Alcohol; Prazosin; Propranolol; Reproducibility of Results; Solid Phase Microextraction; Spironolactone; Valsartan

2020